Remove tag ma
article thumbnail

Drug Regulatory Affairs Certificate Institutes in India

Pharma Tutor

This has also resulted into stricter norms for Marketing Authorization (MA) and Good Manufacturing Practices (GMPs). Mon, 07/18/2022 - 15:31. Read more about Drug Regulatory Affairs Certificate Institutes in India Log in or register to post comments

Drugs 59
article thumbnail

Grand Rounds Ethics and Regulatory Series February 10, 2023: Informing and Consenting: What Are the Goals? (P. Pearl O’Rourke, MD; David S. Wendler, PhD, MA; Miguel Vazquez, MD; P. Michael Ho, MD, PhD)

Rethinking Clinical Trials

Tags #pctGR, @Collaboratory1 The post Grand Rounds Ethics and Regulatory Series February 10, 2023: Informing and Consenting: What Are the Goals? (P. Wendler, PhD, MA; Miguel Vazquez, MD; P. Opt-outs were different across health systems. Pearl O’Rourke, MD; David S. Michael Ho, MD, PhD) appeared first on Rethinking Clinical Trials.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Orphan drugs and where to launch them: The keys to Europe’s forgotten territories

Pharmaceutical Technology

Due to the high price tags associated with these speciality medicines, innovators have naturally favoured big markets with high GDP such as the US and EU-5 (Germany, France, Spain, Italy, and the UK). “The Go-to-market strategies. The choice of where to launch an orphan drug is an important and difficult decision.

Drugs 147
article thumbnail

Grand Rounds April 21, 2023: Personalised Cooler Dialysate for Patients Receiving Maintenance Haemodialysis (MyTEMP): A Pragmatic, Cluster-randomised Trial (Amit Garg, MD, MA, FRCPC, FACP, PhD; Stephanie N. Dixon, PhD MSc)

Rethinking Clinical Trials

Tags #pctGR, @Collaboratory1 The post Grand Rounds April 21, 2023: Personalised Cooler Dialysate for Patients Receiving Maintenance Haemodialysis (MyTEMP): A Pragmatic, Cluster-randomised Trial (Amit Garg, MD, MA, FRCPC, FACP, PhD; Stephanie N. Dixon, PhD MSc) appeared first on Rethinking Clinical Trials.

Trials 130
article thumbnail

Moving to component management & traceability: progress, barriers, and the way forward

pharmaphorum

The process starts adding fields to regulatory submission templates that will incorporate re-used information, then building templates with standardized structures and including structured data tags and sources. Fillable metadata is next added to the templates. He is a strong proponent of standards and data governance.